🧠 neurology

In vivo mapping of striatal neurodegeneration in Huntington's disease with Soma and Neurite Density Imaging

This study demonstrates that Soma and Neurite Density Imaging (SANDI) effectively detects Huntington's disease-related striatal neurodegeneration by revealing reduced soma density and increased soma size, which significantly correlate with motor impairment and striatal atrophy, positioning SANDI as a promising non-invasive biomarker for clinical trials.

Original authors: Ioakeimidis, V., Palombo, M., Casella, C., Layland, L., McNabb, C., Schubert, R., Pallmann, P., Busse, M., Drew, C., Alusi, S., Harrower, T., Davies, J., Rosser, A., Metzler-Baddeley, C.

Published 2026-02-04

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Ioakeimidis, V., Palombo, M., Casella, C., Layland, L., McNabb, C., Schubert, R., Pallmann, P., Busse, M., Drew, C., Alusi, S., Harrower, T., Davies, J., Rosser, A., Metzler-Baddeley, C.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: Huntington's Disease as a "City in Decline"

Imagine the brain is a bustling city. In Huntington's Disease (HD), a specific neighborhood in this city called the Basal Ganglia (specifically the striatum) starts to crumble. This neighborhood controls movement and coordination. As it falls apart, people lose their ability to move smoothly, think clearly, and function normally.

For a long time, doctors have tried to measure how bad the damage is by looking at the size of the neighborhood from the outside (like measuring the square footage of a building). They know the building is shrinking, but they can't see why it's shrinking just by looking at the size. Is the furniture gone? Are the walls crumbling? Are there too many weeds growing in the empty spaces?

The New Tool: "SANDI" (The Microscope)

This study introduces a new, high-tech way to look inside the brain called SANDI (Soma and Neurite Density Imaging).

Think of SANDI as a super-powered microscope that uses magnetic waves instead of light. While a regular MRI is like taking a photo of a house from the street (telling you the house is smaller), SANDI is like sending a drone inside to count the bricks, the pipes, and the empty spaces.

SANDI measures three specific things inside the brain cells:

Soma Density: How many "houses" (cell bodies) are there?
Soma Size: How big are those houses?
Extracellular Space: How much empty space (or "weed-filled gaps") is left between the houses?

What the Researchers Found

The team scanned 56 people with Huntington's and 57 healthy people using a very powerful MRI machine. Here is what they discovered in the "crumbling neighborhood":

1. The Houses are Disappearing (Reduced Soma Density)
In people with HD, the SANDI tool found fewer cell bodies (somas) in the basal ganglia.

Analogy: It's like walking through a neighborhood and realizing that 30% of the houses have simply vanished. This matches what scientists already knew from studying brains after death: the specific nerve cells that control movement are dying off.

2. The Remaining Houses are Getting Weirdly Big (Increased Soma Size)
Strangely, the cell bodies that were still there appeared larger than normal.

Analogy: Imagine the remaining houses look swollen or puffy. The researchers believe this isn't because the houses are healthy and growing; it's likely because the "gardeners" (immune cells called glia) are swelling up in response to the damage, or the remaining houses are shrinking in a way that makes them look different to the scanner.

3. The Gaps are Filling with "Weeds" (Increased Extracellular Space)
There was more empty space between the cells, and the fluid in those gaps was behaving differently.

Analogy: As the houses disappear, the empty lots get bigger. The "weeds" (fluid) take over the space where the cells used to be.

4. The "White Matter" Roads Were Fine
The study also looked at the "roads" connecting the neighborhood (neurites). Surprisingly, the density of these roads didn't change much in this specific group.

Analogy: The main highways were still there, even though the houses along the side were gone.

Connecting the Dots: Size vs. Movement

The researchers wanted to know: Does this "microscopic" damage matter to the person's daily life?

The Link: They found a direct connection. The more the "houses" disappeared and the more "empty space" appeared, the worse the person's motor skills were.
The Test: Participants did finger-tapping tasks (like drumming fingers quickly). Those with the most "vanished houses" and "swollen gaps" were the slowest and least accurate at tapping.
The Prediction: The SANDI measurements were so good that they could explain up to 63% of why the brain neighborhood was shrinking. In other words, if you know the cell density and size, you can predict almost exactly how much the brain has atrophied (shrunk).

Why This Matters (According to the Paper)

The paper argues that while measuring the size of the brain area is good, measuring the microscopic composition (using SANDI) gives a much clearer picture of what is actually happening inside.

Current Status: This is a research study. The authors state that SANDI shows promise as a "biomarker" (a biological signpost) for clinical trials.
The Goal: If new drugs are developed to stop Huntington's, doctors need a way to see if the drug is working before the brain shrinks visibly. SANDI might be able to detect if the "houses" stop disappearing or if the "swelling" stops, acting as an early warning system for treatment success.

Summary

This study used a special MRI technique (SANDI) to look inside the brains of people with Huntington's. They found that the disease causes cell bodies to vanish and the remaining space to fill with fluid, which directly correlates with how poorly a person can move their fingers. This new way of looking at the brain offers a more detailed map of the damage than simply measuring how big the brain is.

Technical Summary: In vivo mapping of striatal neurodegeneration in Huntington's disease with Soma and Neurite Density Imaging

Problem Statement
Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by the early loss of medium spiny neurons (MSN) in the striatum, leading to motor, cognitive, and psychiatric decline. While volumetric MRI is the current gold standard for tracking disease progression and is incorporated into the Huntington's Disease Integrated Staging System (HD-ISS), it lacks specificity regarding the underlying microstructural tissue changes, such as neuronal loss versus glial reactivity. Conventional diffusion tensor imaging (DTI) has shown alterations in mean diffusivity (MD) and fractional anisotropy (FA) in HD, but these metrics are non-specific and model water diffusion as a single Gaussian tensor, failing to distinguish between intracellular (soma and neurites) and extracellular compartments. There is a critical need for sensitive, non-invasive imaging biomarkers that can provide biologically interpretable measures of grey matter microstructure to serve as surrogate outcome measures for emerging disease-modifying therapies.

Methodology
The study utilized a multi-shell diffusion-weighted imaging (DWI) protocol acquired on a 3T Siemens Connectom scanner equipped with ultra-strong gradients (300 mT/m). The cohort consisted of 56 individuals with HD (mean age 46.1) and 57 age- and sex-matched healthy controls (HC).

Acquisition: High-angular resolution DWI data were collected across six b-values ranging from 200 to 6,000 s/mm², enabling the separation of diffusion signals from different tissue compartments. T1-weighted anatomical images were also acquired for segmentation.
Modeling: The study applied Soma and Neurite Density Imaging (SANDI), a biophysical model that decomposes the diffusion signal into three compartments: restricted diffusion within spheres (somas), restricted diffusion within cylinders (neurites), and Gaussian diffusion in the extracellular space. This yields specific indices: apparent soma density ( $f_{is}$ ), apparent soma size ( $r_s$ ), apparent neurite density ( $f_{in}$ ), extracellular signal fraction ( $f_{ec}$ ), and extracellular diffusivity ( $D_e$ ).
Analysis: Regions of interest (ROIs) including the caudate, putamen, globus pallidum, and thalamus were segmented bilaterally. Microstructural indices were extracted and compared between groups using non-parametric tests. Hierarchical linear regression was employed to determine the extent to which SANDI indices, alongside age and clinical scores (TFC), predicted volumetric atrophy. Motor performance was assessed using the Quantitative Motor (Q-Motor) battery, reduced to a single principal component via PCA. Correlations were analyzed between imaging metrics, motor performance, and disease burden (CAP100 score).

Key Contributions and Results
The study provides the first in vivo characterization of HD-related microstructural abnormalities in the basal ganglia using SANDI.

Microstructural Specificity: Compared to HC, HD participants exhibited significantly reduced apparent soma density and increased apparent soma size in the basal ganglia (caudate, putamen, and pallidum), but not in the thalamus. Additionally, the extracellular signal fraction and extracellular diffusivity were elevated in the basal ganglia of HD patients. No significant differences were found in apparent neurite density.
Correlation with Pathology and Function: The reduction in apparent soma density and increase in apparent soma size align with ex vivo evidence of MSN loss and reactive gliosis (glial swelling). These SANDI indices correlated significantly with motor performance (Q-Motor component) and disease burden (CAP100). Specifically, lower soma density and higher extracellular fractions were associated with greater motor impairment.
Explaining Atrophy: Hierarchical regression analyses revealed that SANDI indices (specifically apparent soma density and size) combined with age explained up to 63% of the variance in striatal atrophy in HD patients. In contrast, age alone was the primary predictor of thalamic volume, and SANDI indices did not significantly predict thalamic volume, consistent with the known trajectory of HD pathology where striatal degeneration precedes thalamic involvement.
Stage Sensitivity: Exploratory analyses suggested that SANDI indices are sensitive to changes across disease stages (HD-ISS 0-3), with differences in soma density and extracellular metrics evident even in early stages (HD-ISS 0-1), though some metrics (like soma size in the pallidum) appeared more pronounced in later stages.

Significance and Claims
The authors claim that SANDI offers a promising avenue for bridging the gap between non-invasive MRI and histopathology. By providing biologically interpretable parameters that reflect tissue composition, SANDI detects neurodegeneration patterns consistent with the loss of medium spiny neurons and glial reactivity. The study concludes that SANDI metrics:

Detect HD-related neurodegeneration in the striatum with sensitivity comparable to or exceeding conventional volumetric and DTI measures.
Account for a substantial proportion of striatal atrophy, offering a mechanistic explanation for macroscopic volume loss.
Correlate with motor impairments and disease burden, supporting their utility as potential surrogate outcome measures for clinical trials of disease-modifying therapies.

The paper maintains a modest tone regarding clinical translation, noting that while the data were acquired on an ultra-strong gradient system, previous work suggests SANDI feasibility on standard clinical scanners. The authors emphasize that these findings require validation in larger, prospective cohorts before SANDI can be established as a definitive biomarker for disease progression.